Kissei Pharmaceutical Full Year 2025 Earnings: Beats Expectations

Simply Wall St · 05/09 22:54

Kissei Pharmaceutical (TSE:4547) Full Year 2025 Results

Key Financial Results

  • Revenue: JP¥88.3b (up 17% from FY 2024).
  • Net income: JP¥12.0b (up 7.2% from FY 2024).
  • Profit margin: 14% (down from 15% in FY 2024).
  • EPS: JP¥274 (up from JP¥247 in FY 2024).
We've discovered 3 warning signs about Kissei Pharmaceutical. View them for free.
earnings-and-revenue-growth
TSE:4547 Earnings and Revenue Growth May 9th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Kissei Pharmaceutical Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 7.6%.

Looking ahead, revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in Japan.

Performance of the Japanese Pharmaceuticals industry.

The company's shares are up 9.5% from a week ago.

Risk Analysis

Before you take the next step you should know about the 3 warning signs for Kissei Pharmaceutical (1 doesn't sit too well with us!) that we have uncovered.